Elena Georgievskaya, MD
Family Medicine · Mc Kees Rocks, PANPI 1457631467
Payments from drug & device makers
Across 709 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- GSK$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- AstraZeneca$742
- plus $4K from 31 others
What the payments were for
- Food & beverage$11,58598%
- Education$1922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $1,705 |
| AbbVie(2 entities) | 85 | $1,609 |
| GSK | 95 | $1,600 |
| Pfizer | 89 | $1,195 |
| Lilly USA, LLC | 63 | $1,061 |
| AstraZeneca | 40 | $742 |
| Amgen | 35 | $614 |
| Boehringer Ingelheim | 41 | $581 |
| Bayer | 26 | $424 |
| Astellas Pharma US Inc | 14 | $354 |
| Sanofi-aventis U.S. LLC | 15 | $253 |
| Merck | 15 | $214 |
| Idorsia Pharmaceuticals US Inc | 12 | $213 |
| E.r. Squibb & Sons, L.L.C. | 11 | $179 |
| Johnson & Johnson | 11 | $178 |
| Corcept Therapeutics | 4 | $114 |
| Azurity Pharmaceuticals, Inc. | 5 | $94 |
| Novartis | 5 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Abiomed | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $40 |
| Radius Health, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Appliedvr Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Pulmonx Corporation | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Biogen | 1 | $12 |
How this compares
$11,777 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $138,357 |
| JardianceEmpagliflozin | 84 | $107,516 |
| OzempicSemaglutide | 73 | $90,425 |
| TradjentaLinagliptin | 93 | $79,147 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $55,525 |
| MounjaroTirzepatide | 33 | $41,127 |
| FarxigaDapagliflozin Propanediol | 43 | $36,785 |
| XareltoRivaroxaban | 30 | $36,073 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 58 | $32,427 |
| TrulicityDulaglutide | 19 | $21,906 |
| RybelsusSemaglutide | 14 | $17,047 |
| VraylarCariprazine Hcl | 12 | $16,279 |
| EntrestoSacubitril/Valsartan | 15 | $15,807 |
| MyrbetriqMirabegron | 18 | $11,668 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $581 | $219,090235 claims |
| PfizerEliquis, Paxlovid | $1,195 | $141,137158 claims |
| Novo NordiskOzempic, Rybelsus | $1,705 | $107,47287 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,600 | $65,47688 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,061 | $63,03352 claims |
| AstraZenecaFarxiga | $742 | $36,78543 claims |
| Johnson & JohnsonXarelto | $178 | $36,07330 claims |
| AbbVieVraylar, Restasis, Synthroid | $1,609 | $26,70699 claims |
| NovartisEntresto | $73 | $15,80715 claims |
| Astellas Pharma US IncMyrbetriq | $354 | $11,66818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Mc Kees Rocks
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.